A multicenter, randomized, parallel-groups, double-blind placebo controlled study comparing the efficacy, safety, and tolerability of co-administration of ezetimibe 10 mg with ongoing treatment with simvastatin 20 mg versus doubling the dose of simvastatin in subjects with primary hypercholesterolemia diabetes mellitus type 2 and coronary heart disease.

Trial Profile

A multicenter, randomized, parallel-groups, double-blind placebo controlled study comparing the efficacy, safety, and tolerability of co-administration of ezetimibe 10 mg with ongoing treatment with simvastatin 20 mg versus doubling the dose of simvastatin in subjects with primary hypercholesterolemia diabetes mellitus type 2 and coronary heart disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2014

At a glance

  • Drugs Ezetimibe (Primary) ; Simvastatin (Primary)
  • Indications Coronary artery disease; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 16 Mar 2010 Actual patient number (93) added as reported by ClinicalTrials.gov.
    • 14 May 2007 Status changed from in progress
    • 10 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top